Department of Medicine, Jiangnan University, Wuxi, 214000, People's Republic of China.
Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangnan University, Wuxi, 214000, People's Republic of China.
J Ovarian Res. 2020 Aug 31;13(1):100. doi: 10.1186/s13048-020-00707-7.
Ovarian cancer typically is diagnosed late because insensitivity and lack of specificity of current biomarkers prior to its clinical detection. Ribosomal protein S6 (RPS6) is a ribosomal protein involved in the ribosomal 40S subunit, but its biological role in epithelial ovarian cancer (EOC) is still unknown.
RPS6 was elevated in EOC compared to normal ovarian tissues and adenomas. Higher expression of RPS6 predicted worse prognosis in EOC. The level of RPS6 was correlated with clinical stage, histological type and pathological grade. Knockdown of RPS6 reduced the proliferation of ovarian cancer cell lines SKOV-3 and HO8910, and inhibit the migration and invasion ability. It revealed that cells arrested at G0G1 phase after knockdown of RPS6, and the expressions of CyclinD1, Cyclin E, CDK2, CDK4, CDK6 and pRb were also reduced.
RPS6 is involved in EOC and knockdown of RPS6 could inhibit the proliferation, invasion and migration ability of EOC in vitro by inducing G0/G1 phase arrest. RPS6 is expected to be a novel biomarker and molecular target to the EOC.
卵巢癌通常在临床检测前由于当前生物标志物的不敏感性和缺乏特异性而被诊断为晚期。核糖体蛋白 S6（RPS6）是一种参与核糖体 40S 亚基的核糖体蛋白，但它在卵巢上皮性癌（EOC）中的生物学作用尚不清楚。
与正常卵巢组织和腺瘤相比，RPS6 在 EOC 中升高。RPS6 的高表达预示着 EOC 的预后不良。RPS6 的水平与临床分期、组织学类型和病理分级相关。RPS6 的敲低减少了卵巢癌细胞系 SKOV-3 和 HO8910 的增殖，并抑制了迁移和侵袭能力。结果表明，RPS6 敲低后细胞停滞在 G0/G1 期，同时细胞周期蛋白 D1、细胞周期蛋白 E、CDK2、CDK4、CDK6 和 pRb 的表达也降低。
RPS6 参与了 EOC，RPS6 的敲低可通过诱导 G0/G1 期停滞，抑制体外 EOC 的增殖、侵袭和迁移能力。RPS6 有望成为一种新的生物标志物和分子靶点用于治疗 EOC。
